AMGN241129C245000
- 31.70
- 0.000.00%
Amgen Newsroom
Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?
Wednesday Ends With Index Decline | Wall Street Today
AMGN Stock Down Despite Strong Data From Obesity Drug Study
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Daily short sale tracking: GameStop's short volume increased by 1 million, with a short sale ratio of 12%
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $305 to $380
Today's Analyst Rating | Amgen Price Target Raised to $305 by Deutsche Bank, Applovin Price Target Raised to $400 by Jefferies
Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete With Blockbuster Tirzepatide, Truist Says
Amgen's Stock Closes off Lows to Avoid Worst Day in 24 Years as Weight-loss-drug Data Underwhelms
Truist Financial Sticks to Their Hold Rating for Amgen (AMGN)
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Express News | Amgen Shares Down 1.6% Premarket ; at Least Two Brokerages Cut PT Following Mid-Stage Data for Weight-Loss Drug
Deutsche Bank Adjusts Price Target on Amgen to $285 From $305, Maintains Hold Rating
Express News | Amgen Inc : RBC Cuts Target Price to $330 From $360
Amgen's MariTide Phase 2 Success Drives Buy Rating Amid Promising Obesity Treatment Prospects